Background: Calcium-independent phospholipase A 2 ␥ (iPLA 2 ␥) is a mediator of complement-induced glomerular injury. Results: Complement stimulated iPLA 2 ␥ through activation of mitogen-activated protein kinases. Conclusion: Phosphorylation of iPLA 2 ␥ plays a role in activation and signaling. Significance: Understanding the regulation of iPLA 2 ␥ activity is essential for developing novel therapeutic approaches to glomerular injury and proteinuria.
contribute to changes in GEC lipid structure and function, actin cytoskeleton reorganization, and displacement of filtration slit diaphragm proteins, ultimately resulting in proteinuria (12, 13, 16) . Recently, we demonstrated that C5b-9 stimulated a Ca 2ϩ -independent PLA 2 activity in GECs, and complement-induced release of [ 3 H]AA and prostaglandin E 2 (PGE 2 ) was amplified in GECs that overexpress iPLA 2 ␥ (13, 16). Furthermore, overexpression of iPLA 2 ␥ attenuated complement-induced GEC injury, and this effect was reversed by the iPLA 2 -directed inhibitor, bromoenol lactone (BEL) as well as indomethacin, suggesting that the cytoprotective effect of iPLA 2 ␥ was at least in part mediated by generation of prostanoids (16) .
Although we and others have shown functional coupling of iPLA 2 ␥ with COX1, leading to prostanoid production (17) , the functions of iPLA 2 ␥ have not been fully delineated (18) . In resting cells, iPLA 2 s, including iPLA 2 ␤, are involved in the maintenance of membrane phospholipids by generating lysophospholipid acceptors that are reacylated with fatty acids. Therefore, iPLA 2 plays a housekeeping role by facilitating phospholipid remodeling (19 -21) . Inhibition of iPLA 2 in HEK293 and INS-1 cells altered the amounts of several phospholipids and resulted in decreased cell growth and p53 activation (22) (23) (24) . During oxidative stress, an ER-associated iPLA 2 in renal proximal tubular cells (iPLA 2 ␥) recognizes, cleaves, and removes oxidized phospholipids from the ER membrane (25) ; thus, iPLA 2 ␥ may act to repair or prevent lipid peroxidation during oxidative stress (25) . Another study demonstrated that expression of shRNA against iPLA 2 ␥ increased lipid peroxidation and induced apoptosis in renal cells (26) . iPLA 2 is involved in signal transduction pathways that include mitogen-activated protein kinase (MAPK) p38, epidermal growth factor (EGF) receptor, the tumor suppressor gene, p53, and cell cycle-regulator, p21 (27) . A diverse array of cellular processes has been proposed to be regulated by iPLA 2 ␥, including cellular proliferation (28) , assembly of very low density lipoprotein (29) , apoptosis (30) , endothelial cell platelet activating factor synthesis (31) , tumorigenesis, cell injury, and chemotaxis (7) . iPLA 2 ␥ is a membrane-bound enzyme that is reported to localize at the ER, peroxisomes, and mitochondria (25) . These distinct sites of localization may be a result of specific domains in the structure of the enzyme (32) . iPLA 2 ␥ gene transcription and translation appear complex, as distinct translation initiation sites, resulting in the production of 88-, 77-, 74-, and 63-kDa forms of the enzyme were reported (33) . iPLA 2 ␥ contains a consensus site for nucleotide binding and a lipase consensus motif in its C-terminal half as well as potential cAMPdependent protein kinase, protein kinase C, and extracellular signal-regulated kinase (ERK) phosphorylation sites (32) . The lipase consensus motif GVSTG (amino acids 481-485 in the C-terminal region) is essential for Ca 2ϩ -independent PLA 2 catalytic activity, and substitution of Ala for Ser-483 or Asp-627 results in loss of PLA 2 activity (34) . To date, it is not known if/how phosphorylation would affect iPLA 2 ␥ activity.
The goal of the present study was to further characterize the activation of iPLA 2 ␥ in complement-induced GEC injury. Specifically, we addressed the role of various kinases known to be activated by complement. In GECs, we demonstrate the subcellular localization of iPLA 2 ␥ at the ER and mitochondria, which was dependent on the N-terminal region of iPLA 2 ␥. Complement-induced activation of iPLA 2 ␥ was mediated via ERK and p38 pathways. Stimulation of iPLA 2 ␥ was dependent on phosphorylation of Ser-511 and/or Ser-515 via MAPK-interacting kinase 1 (MNK1).
EXPERIMENTAL PROCEDURES
Materials-Tissue culture media, G418 (Geneticin), plasmid pRc/RSV, and Lipofectamine 2000 were from Invitrogen. Electrophoresis reagents were from Bio-Rad. Mouse monoclonal anti-green fluorescent protein (GFP), sheep anti-COX1, rabbit anti-MEK1 (C-18), and rabbit anti-MAP/ERK kinase kinase 1 (MEKK1) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-calnexin was from Assay Designs and Stressgen (Ann Arbor, MI). Mouse monoclonal anti-␣-tubulin was from Sigma. Rabbit phospho-p44/42 MAPK (Thr-202/Tyr-204), rabbit anti-phospho-p38 (Thr-180/Tyr-182), rabbit anti-phospho-JNK (Thr-183/Tyr-185), and rabbit antiphospho-Ser/Thr Akt substrate antibody (which recognizes the sequence (R/K)XX(pS/T)) were from Cell Signaling Technology (Danvers, MA). MitoTracker Red CMXRos was from Molecular Probes (Eugene, OR). Enhanced chemiluminescence (ECL) reagents were from GE Healthcare. BEL, CGP57380, PLA 2 assay kits and PGE 2 enzyme immunoassay kits were from Cayman Chemical (Ann Arbor, MI). PD98059 was from Calbiochem. Human iPLA 2 ␥ wild type (WT) in pcDNA 1.1 was kindly provided by Drs. Richard Gross and David Mancuso (Washington University School of Medicine, St. Louis, MO) (16) . R4F-MEK cDNA was provided by Dr. Natalie Ahn (University of Colorado, Boulder, CO) (35) . pFC-MEKK, the constitutively active form of MEKK1, and pFC-MKK3, the constitutively active form of MKK3, were from Stratagene (La Jolla, CA). C8 and C8-deficient serum were from Complement Technology (Tyler, TX). pcDNA3-myc-MAPK-activated protein kinase-2 (MK2) WT and constitutively active mutant cDNA3-myc-MK2-EE were kindly provided by Professor Matthias Gaestel (Institute of Biochemistry, Medical School, Hannover, Germany) (36) . Constructs encoding glutathione S-transferase (GST)-tagged MNK1 (pEBG-MNK1), a constitutively active form of MNK1 (pEBG-T332D), dominant-interfering MNK1 mutant (pEBG-T2A2), and pEBG empty vector were kindly provided by Dr. Jonathan Cooper (Fred Hutchinson Cancer Research Center, Seattle, WA) (37) . Other reagents were from Sigma.
Cloning and Construction of iPLA 2 ␥ Mutants-WT, fulllength (782 amino acid; M1) human iPLA 2 ␥ in pcDNA 1.1 was digested with SalI and SacII and was subcloned into pEGFP-C1 vector (Clontech) at SalI and SacII restriction sites to produce M1 GFP-iPLA 2 ␥ WT (M1 denotes that the iPLA 2 ␥ cDNA sequence begins at the codon for the first methionine). Mutations in potential ERK phosphorylation sites (Ser-271 and Ser-168 to Ala as well as the double mutation) were constructed by PCR-based mutagenesis (primers are presented in Table 1 ). A double mutation in two other potential phosphorylation sites (Ser-511 and Ser-515 to Ala) was constructed using an analogous approach (Table 1) . For construction of N-terminally truncated (M4) GFP-iPLA 2 ␥ (i.e. iPLA 2 ␥ cDNA sequence beginning at the codon for the 4th methionine, amino acid 221) PCR reactions were performed with primers M4-F1 in combination with R1 (Table 1 ). All GFP-iPLA 2 ␥ mutant cDNAs were verified by DNA sequencing.
Cell Culture and Transfection-Rat GEC culture and characterization have been described previously (38) . GECs were maintained in K1 medium on plastic substratum. Cells were stably transfected with M1 or M4 GFP-iPLA 2 ␥ WT plasmids using Lipofectamine 2000 reagent according to the manufacturer's instructions. After selection with G418 and expansion, cells were sorted by flow cytometry to obtain cells with the highest expression of GFP-iPLA 2 ␥ WT. Fluorescence microscopy and immunoblotting were used to confirm GFP-iPLA 2 ␥ overexpression. A clone of GECs containing the neomycin-resistance gene was used as a control (GEC-Neo). COS-1 cells were cultured in DMEM, 10% fetal bovine serum and were transfected transiently with GFP-iPLA 2 ␥ and/or COX1 cDNAs using Lipofectamine 2000.
Incubation of GECs with Complement-GECs in monolayer culture were washed twice and incubated with rabbit anti-GEC antiserum (5% v/v) in modified Krebs-Henseleit buffer containing 145 mM NaCl, 5 mM KCl, 0.5 mM MgSO 4 , 1 mM Na 2 HPO 4 , 0.5 mM CaCl 2 , 5 mM glucose, and 20 mM Hepes, pH 7.4, for 30 min at 22°C. The cells were then incubated for 40 min at 37°C with normal human serum (NS, 2% v/v; with full complement activity) or heat-inactivated (decomplemented) human serum (HIS, 2% v/v; incubated at 56°C for 60 min) in controls (39, 40) . PGE 2 Assay-Stimulated iPLA 2 enzymatic activity was monitored by measuring PGE 2 production. After incubation, supernatants were collected to quantify PGE 2 . The amount of PGE 2 released into supernatants was equivalent to that from cells plus supernatants, indicating that most PGE 2 was released from cells into supernatants. PGE 2 was quantified using an enzyme immunoassay kit according to the manufacturer's instructions. The range of the standard curve in the assay was 4 -1000 pg of PGE 2 /100 l of sample (41) . PGE 2 concentration was calculated according to standard formulas.
PLA 2 Assay-PLA 2 activity was measured in COS-1 cell extracts using a PLA 2 activity assay kit according to the manufacturer's instructions and as described previously (42) . In this assay, hydrolysis of arachidonoyl thiophosphatidylcholine at the sn-2 position by PLA 2 releases a free thiol that is detected by 5,5Ј-dithio-bis-2-nitrobenzoic acid. Briefly, cells were homogenized in 50 mM Hepes, pH 7.4, containing 1 mM EDTA. Cell homogenates were cleared by centrifugation at 8500 ϫ g for 10 min at 4°C. The reaction was initiated by the addition of 2-arachidonoyl thiophosphatidylcholine to cell extracts in buffer containing 80 mM Hepes, pH 7.4, 150 mM NaCl, 4 mM Triton X-100, 30% glycerol, and 1 mg/ml BSA. Duplicate samples were incubated with and without 10 M BEL. After 60 min at 22°C, the reaction was terminated by the addition of 1 mM 5,5Ј-dithio-bis-2-nitrobenzoic acid, and the absorbance was measured at 450 nm. To determine iPLA 2 activity, the optical density obtained in the presence of BEL was subtracted from the total optical density (42) (in control cells, ϳ20% of PLA 2 activity was inhibited by BEL). The value of the group with maximum iPLA 2 activity was set to 1.0, and the iPLA 2 activities of the other groups were calculated as percent of maximum.
Immunoblotting-Cells were lysed in ice-cold buffer containing 1% Triton X-100, 125 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 2 mM Na 3 VO 4 , 10 mM sodium pyrophosphate, 25 mM NaF, and protease inhibitor mixture (Roche Diagnostics). Equal amounts of lysate proteins were dissolved in Laemmli buffer and subjected to SDS-PAGE under reducing conditions. Proteins were then electrophoretically transferred onto a nitrocellulose membrane and blocked at room temperature for 60 min with 5% dry milk in buffer containing 10 mM Tris, pH 7.5, 50 mM NaCl, 2.5 mM EDTA, and 0.05% Tween 20. The membrane was then incubated with primary and secondary antibodies and developed with ECL.
Immunofluorescence Microscopy-GECs expressing GFPiPLA 2 ␥ WT (M1 or M4) and GEC-Neo (control) were cultured on glass coverslips for 24 h. All reactions were carried out at 22°C. To examine the localization of GFP-iPLA 2 ␥ WT at the ER, cells were fixed with 3% paraformaldehyde in PBS for 30 min and permeabilized with 0.1% Triton-X 100 in PBS for 30 min. After washing with PBS, GECs were incubated with rabbit anti-calnexin antiserum or normal rabbit serum (negative control) diluted in 3% BSA for 30 min. Cells were washed and incubated with rhodamine-conjugated goat anti-rabbit IgG in 3% BSA for 30 min. Nuclei were counter-stained with 4Ј6-diamindino 2-phenylindole (DAPI, 30 nM) in PBS for 4 -5 min just before mounting the coverslips onto glass slides. Staining was visualized with a Zeiss AxioObserver fluorescence microscope with visual output connected to an AxioCam digital camera. To visualize mitochondria, GECs expressing GFP-iPLA 2 ␥ WT (M1 or M4) and GEC-Neo (control), on coverslips were incu- 
CCTTGTTCCTCCACCATCAA bated for 15 min at 37°C with MitoTracker Red CMXRos (25 nM). Cells were then fixed with 3% (w/v) paraformaldehyde in PBS for 30 min. After washing, coverslips were mounted onto glass slides and visualized with a fluorescence microscope. Statistics-Data are presented as the mean Ϯ S.E. One-way analysis of variance was used to determine significant differences among groups. Where significant differences were found, individual comparisons were made between groups using the t-statistic and by adjusting the critical value according to Tukey's or Bonferroni's method. Statistical significance was considered to be p Ͻ 0.05.
RESULTS
M1 GFP-iPLA 2 ␥ WT Is Enzymatically Active-To study the effect of complement on iPLA 2 ␥ activation, we first established a subclone of GECs that stably overexpresses M1 GFP-iPLA 2 ␥ WT (M1 GEC-iPLA 2 ␥). By immunoblotting, M1 GEC-iPLA 2 ␥ was expressed as a 115-kDa protein, consistent with GFP (27 kDa) fused with the 88-kDa isoform of iPLA 2 ␥ (Fig. 1A) . When M1 GFP-iPLA 2 ␥ WT or untagged iPLA 2 ␥ was transfected in COS-1 cells together with COX1, PGE 2 production was markedly increased compared with untransfected control (Fig. 1B ) or cells transfected with COX1 alone (Fig. 1C ). This increase was attenuated by the addition of BEL (Fig. 1C) . Together the results indicate that M1 GFP-iPLA 2 ␥ WT is enzymatically active.
iPLA 2 ␥ Localizes at the ER and Mitochondria-The expression and localization of iPLA 2 isoforms varies considerably among different cell types, and the role of iPLA 2 may be determined by the isoform present in a specific cell or organelle (43) . We examined the localization of M1 GFP-iPLA 2 ␥ WT in stably transfected GECs. By fluorescence microscopy, confluent monolayers of resting GECs demonstrated green fluorescent staining mainly in the perinuclear region (Fig. 2 , A and C). A significant portion of the M1 GFP-iPLA 2 ␥ WT co-localized with calnexin (Fig. 2, B and D) , indicating localization at the ER.
In resting cells not expressing M1 GFP-iPLA 2 ␥ WT, calnexin staining showed a similar distribution in the perinuclear region, indicating that expression of M1 GFP-iPLA 2 ␥ WT did not affect the structure of the ER (data not shown).
A portion of the M1 GFP-iPLA 2 ␥ WT did not appear to colocalize with calnexin but localized at the mitochondria (Fig. 2 , E-G). The appearance of the mitochondria was unaffected by the expression of M1 GFP-iPLA 2 ␥ WT (data not shown). Finally, we treated the GECs expressing M1 GFP-iPLA 2 ␥ WT with digitonin to permeabilize the plasma membranes and release cytosolic proteins into cell supernatants. Distribution of the GFP fluorescence in the digitonin-treated cells was similar to that seen in untreated (intact) cells (Fig. 2H ), further supporting the association of iPLA 2 ␥ with intracellular organelles. Together the results shown in Fig. 2 indicate that in GECs M1 GFP-iPLA 2 ␥ WT is associated with at least two organelles, the ER and mitochondria.
N-terminally Truncated iPLA 2 ␥ (M4 GFP-iPLA 2 ␥) Is Mislocalized-The catalytic domain of iPLA 2 ␥ is located in the C-terminal region of the protein, whereas the role of the N-terminal region is poorly defined. Indeed, a previous study showed that iPLA 2 ␥ contains four N-terminal methionine residues that may act as translation initiation sites, resulting in 88-, 77-, 74-, and 63-kDa forms of iPLA 2 ␥ in SF9 insect cells (33) . To determine if the N-terminal region may be involved in localization and/or regulation of iPLA 2 ␥ catalytic activity, we deleted the 220 N-terminal amino acids (spanning between the 1st and 4th methionine) to generate a short form of iPLA 2 ␥ in which the GFP-iPLA 2 ␥ fusion would be at the 4th methionine (M4 GFPiPLA 2 ␥). Expression of M4 GFP-iPLA 2 ␥ in COS-1 cells showed a prominent band at ϳ92 kDa (Fig. 3A ) that represents GFP (27 kDa) fused with the 63-kDa form of iPLA 2 ␥. When both M1 and M4 isoforms were expressed at serially increasing concentrations in COS-1 cells (together with COX1), PGE 2 production by M1 GFP-iPLA 2 ␥ WT was markedly greater compared with FIGURE 1. Expression and activity of M1 GFP-iPLA 2 ␥ WT. A, GECs were stably transfected, and COS-1 cells were transiently transfected with M1 GFP-iPLA 2 ␥ WT or a GFP-rac fusion protein for comparison. Lysates were immunoblotted with antibody to GFP. * denotes M1 GFP-iPLA 2 ␥ in GECs, which migrated slower than M1 GFP-iPLA 2 ␥ in COS-1 cells, possibly because of differential post-translational modifications in the two cell lines. B, COS-1 cells were transiently transfected with untagged full-length iPLA 2 ␥, M1 GFP-iPLA 2 ␥ WT, and COX1. PGE 2 production was measured in cell supernatants 24 h after transfection. Both GFP-tagged and untagged enzymes increased PGE 2 release. *, p Ͻ 0.001 iPLA 2 ␥ ϩ COX1 and GFP-iPLA 2 ␥ ϩ COX1 versus untransfected (Untransf) cells, three experiments. C, COS-1 cells were untransfected or were transiently transfected with vector, M1 GFP-iPLA 2 ␥ WT, COX1, or M1 GFP-iPLA 2 ␥ WT ϩ COX1. Expression of COX1 alone increased PGE 2 release compared with control, whereas GFP-iPLA 2 ␥ ϩ COX1 substantially amplified the increase in PGE 2 production. This increase was inhibited by coincubation with 30 M BEL (6 h). *, p Ͻ 0.001 GFP-iPLA 2 ␥ ϩ COX1 versus untransfected or vector and p Ͻ 0.001 GFP-iPLA 2 
M4 GFP-iPLA 2 ␥ despite weaker expression (Fig. 3, A-C) . PGE 2 production by M4 GFP-iPLA 2 ␥ was trivial, as it was not significantly greater compared with control cells.
We also employed an in vitro assay to measure iPLA 2 enzymatic activity in extracts of control COS-1 cells and COS-1 cells expressing M1 GFP-iPLA 2 ␥ WT or M4 GFP-iPLA 2 ␥. Using 2-arachidonoyl phosphatidylcholine as substrate, M1 GFPiPLA 2 ␥ WT activity was significantly greater than control. M4 GFP-iPLA 2 ␥ also demonstrated significant activity (Fig. 3D) . Thus, M4 GFP-iPLA 2 ␥ is active in vitro but not in intact cells.
In the next set of experiments, we employed GECs stably transfected with M4 GFP-iPLA 2 ␥ (Fig. 3C) to examine the localization. M4 GFP-iPLA 2 ␥ was found mainly in the cytosol, and only a minor portion was co-localized with calnexin (Fig. 2 , I-L). Some cells contained what appeared to be aggregates of M4 GFP-iPLA 2 ␥ (Fig. 2I) . M4 GFP-iPLA 2 ␥ did not co-localize with Mitotracker red (Fig. 2, M-P) . Thus, deletion of the N-terminal region of iPLA 2 ␥ leads to mislocalization of the enzyme away from the ER and mitochondria. Taken together, M4 GFPiPLA 2 ␥ is enzymatically active but may not be functional in releasing AA and PGE 2 in intact cells due to the mislocalization of the enzyme from the membrane containing the substrate.
Complement Induces Release of PGE 2 in GECs That Overexpress iPLA 2 ␥-A previous study demonstrated that in GECs, complement can induce release of [ 3 H]AA via activation of iPLA 2 ␥ (16). Consistent with the previous results, when GECNeo cells were incubated with antibody and sublytic NS (to form C5b-9) or HIS in controls, PGE 2 production increased significantly, which was inhibited by R-BEL, a specific inhibitor of iPLA 2 ␥ (Fig. 4A) . Next, we compared PGE 2 release in M1 GEC-iPLA 2 ␥ and GEC-Neo. Overexpression of M1 GFPiPLA 2 ␥ WT did not affect the basal PGE 2 production (during incubation with HIS). However, after incubation with complement, PGE 2 release was significantly amplified in M1 GECiPLA 2 ␥ compared with GEC-Neo (Fig. 4B) , and the complement-mediated PGE 2 release in M1 GEC-iPLA 2 ␥ was almost completely inhibited by BEL (racemic mixture, non-selective inhibitor of iPLA 2 ␤ and -␥) (Fig. 4B ), in keeping with earlier results (16) . Therefore, activation of complement is coupled with stimulation of iPLA 2 ␥ activity. To verify that the PGE 2 release produced by antibody and NS was actually due to formation of C5b-9, antibody-sensitized M1 GEC-iPLA 2 ␥ were exposed to C8-deficient serum or C8-deficient serum reconstituted with C8 (40). C8-deficient serum alone had no significant effect on PGE 2 production, whereas C8-deficient serum reconstituted with C8 increased PGE 2 release significantly (Fig. 4C) .
We also tested the effect of complement on PGE 2 release in the GECs stably expressing M4 GFP-iPLA 2 ␥. In contrast to M1 GEC-iPLA 2 ␥, the effect of complement on PGE 2 production in the M4-expressing cells was not significantly different from GEC-Neo (Fig. 4D) . The result indicates that M4 GFP-iPLA 2 ␥ is less active in the cell and is in keeping with the experiments involving transient transfection of the M1 and M4 forms of iPLA 2 ␥ in COS-1 cells (Fig. 3B) .
Role of MAPKs in iPLA 2 ␥ Activation-The C5b-9 complex is assembled in the plasma membranes of cells, whereas iPLA 2 ␥ is localized at the ER and mitochondria, i.e. at organelles generally separated from the plasma membrane. It is, therefore, unlikely that C5b-9 interacts with iPLA 2 ␥ directly. Instead, it is reason- WT. Expression tended to increase with increasing doses of plasmid DNA. The lower band in the M1 lanes is nonspecific. B, PGE 2 release in COS-1 cells expressing M4 GFP-iPLA 2 ␥ or M1 GFP-iPLA 2 ␥ WT (both with COX1) was normalized for corresponding protein expression. In these experiments basal PGE 2 release (untransfected cells) was 38.2 pg/ml. PGE 2 production by M1 GFP-iPLA 2 ␥ WT was markedly greater compared with M4 GFP-iPLA 2 ␥. *, p Ͻ 0.0001 M4 ϩ COX1 (0.5, 0.3, and 0.1 g) versus M1 ϩ COX1 (1, 0.7, and 0.5 g), three experiments. C, GECs were stably transfected, and COS-1 cells were transiently transfected with M4 GFP-iPLA 2 ␥. GEC-Neo and COS-1 cells transiently transfected with M1 GFP-iPLA 2 ␥ WT are presented for comparison. Lysates were immunoblotted with antibody to GFP. * denotes M4 GFP-iPLA 2 ␥ in GECs. The bands in GEC-Neo and untransfected COS-1 cells are nonspecific. D, PLA 2 activity in untransfected (control) COS-1 cells and COS-1 cells expressing M1 GFP-iPLA 2 ␥ WT, M1 GFP-iPLA 2 ␥ S511A/S515A double mutant, and M4 GFP-iPLA 2 ␥ is shown. Cell extracts were prepared 24 h after transfection, and iPLA 2 activity was monitored by release of AA from 2-arachidonoyl-phosphatidylcholine ("Experimental Procedures"). iPLA 2 activities of M1 GFPiPLA 2 ␥ WT and M4 GFP-iPLA 2 ␥ were significantly greater compared with control. iPLA 2 activity of M1 GFP-iPLA 2 ␥ S511A/S515A tended to be greater than control. *, p Ͻ 0.01 M1 GFP-iPLA 2 ␥ WT versus control, **, p Ͻ 0.05 M4 GFPiPLA 2 ␥ WT versus control, four experiments. In these experiments basal iPLA 2 activity (control cells) was 0.69 nmol/min/ml. E, cell lysates were immunoblotted with antibodies to GFP (iPLA 2 ␥), actin, or calnexin (marker of ER). FIGURE 4. Complement induces production of PGE 2 via iPLA 2 ␥. A, shown is the role of endogenous iPLA 2 ␥. Neo GECs were incubated with anti-GEC antiserum for 30 min at 22°C in the presence or absence of the iPLA 2 ␥-directed inhibitor R-BEL (10 M). Cells were then incubated at 37°C with 2% NS (to form C5b-9) or HIS in controls with or without R-BEL for 40 min. Then PGE 2 production was measured in cell supernatants. Complement stimulated PGE 2 production, and the increase was significantly attenuated by R-BEL. *, p Ͻ 0.0001 NS versus HIS and p Ͻ 0.001 NS versus NS/R-BEL, three experiments. B, complement-induced production of PGE 2 is amplified in GECs that overexpress M1 GFP-iPLA 2 ␥ WT (GEC GFP-iPLA 2 ␥). GECs that express M1 GFP-iPLA 2 ␥ WT were incubated with antibody and complement with or without BEL as above. M1 GFP-iPLA 2 ␥ WT markedly amplified complement-induced PGE 2 production, and the increase was attenuated by BEL (30 M). *, p Ͻ 0.001 GEC-GFP-iPLA 2 ␥ (NS) versus GEC-Neo (NS), p Ͻ 0.001 GEC-GFP-iPLA 2 ␥ (NS/ BEL) versus GEC-GFP-iPLA 2 ␥ (NS), three experiments. C, PGE 2 production is dependent on C5b-9 assembly. GECs that express M1 GFP-iPLA 2 ␥ WT were incubated with antibody and C8-deficient serum (C8DS) with or without purified C8. When C8DS was reconstituted with C8, PGE 2 production amplified significantly. *, p Ͻ 0.0001 NS versus HIS; **, p Ͻ 0.001 C8DSϩC8 versus C8DS, 3 experiments. D, M4 GFP-iPLA 2 ␥ is inactive in intact GECs. Neo GECs or GECs that stably express M1 GFP-iPLA 2 ␥ WT or M4 GFP-iPLA 2 ␥ were incubated with antibody and complement as above. *, p Ͻ 0.001 GEC-M1 GFP-iPLA 2 ␥ WT (NS) versus GEC-Neo (NS) and p Ͻ 0.001 GEC-M1 GFP-iPLA 2 ␥ WT (NS) versus GEC-M4 GFP-iPLA 2 ␥ (NS), three experiments.
able to propose that C5b-9 may activate iPLA 2 ␥ via intermediary signals. C5b-9 has been shown to increase the cytosolic Ca 2ϩ concentration and activate MAPKs, including ERK, JNK, and p38 (39) . In the next series of experiments we examined if complement-induced activation of iPLA 2 ␥ was mediated through these MAPK pathways. We employed several MAPK pathway inhibitors including the MEK1 inhibitor, PD98059, the p38 inhibitor SB203580, and the JNK inhibitor SP600125 (44). M1 GEC-iPLA 2 ␥ were preincubated with each inhibitor and were then incubated with antibody and complement (Fig.  5A) . The complement-induced release of PGE 2 was inhibited significantly by SB203580 and PD98059. SP600125 tended to decrease the complement-mediated production of PGE 2 , but the effect was not significant. PD98059 and SB203580 were reported to cross-react and inhibit COX1 and COX2 activities (45) . We, therefore, tested FR167653 and U0126, inhibitors of p38 and MEK1, respectively, which do not inhibit COX1 and COX2 (46) and are structurally distinct from SB203580 and PD98059. Both FR167653 and U0126 inhibited the complement-mediated production of PGE 2 (Fig. 5B) , confirming a role for p38 and ERK pathways in iPLA 2 ␥ activation by complement.
MAPKs Enhance iPLA 2 ␥ Activity in COS-1 Cells-To confirm the role of MAPK pathways in the regulation of iPLA 2 ␥ activity, we transiently co-transfected COS-1 cells with M1 GFP-iPLA 2 ␥ WT, COX1, and constitutively active mutants of MEK1 (kinase upstream of ERK), MEKK1 (kinase upstream of JNK and possibly p38), and MKK3 (kinase upstream of p38). All three constitutively active mutants enhanced PGE 2 production compared with control (vector) (Fig. 6) .
The expression and function of the constitutively active mutants were evaluated in the same sets of experiments. Constitutively active MEK1 migrated slightly faster than the endogenous MEK1 (45 kDa) (Fig. 7A) . ERK phosphorylation (which reflects ERK activation) was increased 1.7-fold by the constitutively active MEK1 (Fig. 7, A and B) , confirming functional activity. Constitutively active MEKK1 was expressed as a protein of ϳ35 kDa (Fig. 7C) , and it stimulated phosphorylation of JNK as expected by ϳ3-fold (Fig. 7, C and D) . In addition, the constitutively active MEKK1 activated the ERK pathway by 2.5-fold (Fig. 7B ) and showed modest but significant activation of the p38 pathway (Fig. 7, E and F) , consistent with earlier studies showing that when overexpressed, the MEKK1 mutant can activate ERK and p38 (47) . Unexpectedly, we could not detect phosphorylation of p38 after transfection of the constitutively active mutant of MKK3 (Fig. 7 , E and F) even though MKK3 increased PGE 2 release (Fig. 6) . Possibly, phosphorylation of p38 was very transient, limiting its detectability. In summary, the results support a role for ERK in the activation of iPLA 2 ␥, as constitutively active protein kinases that stimulated ERK phosphorylation also stimulated iPLA 2 ␥ activity, and complementstimulated iPLA 2 ␥ activity was blocked by ERK pathway-directed inhibitors. By analogy, p38 may also stimulate iPLA 2 ␥, as constitutively active MEKK1 stimulated iPLA 2 ␥ and p38 phosphorylation, and complement-stimulated iPLA 2 ␥ activity was blocked by p38 inhibitors. However, the role of MKK3 could not be established definitively and will require additional study. Finally, the results do not support a role for JNK in the activation of iPLA 2 ␥. EGF Together with Ionomycin Enhances iPLA 2 ␥ Activity in COS-1 Cells-EGF is a well known activator of the ERK pathway, and COS-1 cells express abundant EGF receptor. To further substantiate the role of the ERK pathway in the activation of iPLA 2 ␥, we investigated the effect of EGF on PGE 2 release in COS-1 cells that were transiently transfected with M1 GFPiPLA 2 ␥ WT (and COX1). Treatment of COS-1 cells with EGF alone did not affect PGE 2 release (Fig. 8A) . Although iPLA 2 is Ca 2ϩ -independent (does not require Ca 2ϩ for its catalytic activity), iPLA 2 activity may nonetheless be regulated by Ca 2ϩ or a Ca 2ϩ -dependent factor (48) . For this reason, we used the Ca 2ϩ ionophore ionomycin to induce a Ca 2ϩ influx. Interestingly, stimulation with EGF in the presence of ionomycin increased PGE 2 release by more than 4-fold compared with EGF alone, ionomycin alone, or untreated (Fig. 8A) . Furthermore, BEL inhibited iPLA 2 ␥ activity induced by EGF ϩ ionomycin significantly (Fig. 8B) . Finally, we confirmed that incubation of COS-1 cells with EGF ϩ ionomycin induced ERK phosphorylation (Fig. 8C) . Thus, the effect of ionomycin ϩ EGF on iPLA 2 ␥ activation is analogous to the effect of C5b-9, which also induces a Ca 2ϩ influx and activation of ERK. Mutations in Putative ERK Phosphorylation Sites Do Not Affect iPLA 2 ␥ Activity-Analysis of the iPLA 2 ␥ protein sequence by the Scansite program (49) suggested that Ser-168 (EKSP amino acid motif) and Ser-271 (PTSP motif) may be ERK phosphorylation sites. Given the substantial evidence for the activation of iPLA 2 ␥ via the ERK pathway, in the next series of the studies we examined if iPLA 2 ␥ may be a direct target of ERK. We constructed three mutant forms of M1 GFP-iPLA 2 ␥, including S168A, S271A, and S168A/S271A double mutation, and tested their activities in COS-1 cells. PGE 2 production stimulated by EGF ϩ ionomycin with the iPLA 2 ␥ mutants did not differ from the WT (Fig. 9A) , whereas the expression levels of all constructs were comparable (Fig. 9B) . Thus, single or double mutations of putative ERK phosphorylation sites did not affect iPLA 2 ␥ activation by EGF ϩ ionomycin, suggesting that the effect of ERK on the stimulation of iPLA 2 ␥ is indirect.
Mutations in Ser-511 and Ser-515 Inhibit iPLA 2 ␥ Activation-A recent phosphoproteomic analysis of mitochondrial proteins in murine heart revealed two iPLA 2 ␥ phosphorylation sites, Ser-505 and Thr-509, corresponding to Ser-511 and Ser-515 in human iPLA 2 ␥ (50). The authors suggested that the two phosphorylation sites (RKLGpSDVFpSQNV) may be in the context of MK2 or casein kinase I substrate motifs (50) . Based on these results, we constructed a S511A/S515A double mutant form of M1 GFP-iPLA 2 ␥ and tested its activity in COS-1 cells. The in vitro enzymatic activity of M1 GFP-iPLA 2 ␥ S511A/S515A in COS-1 cells tended to be greater compared with control but was lower compared with M1 GFP-iPLA 2 ␥ WT (Fig. 3D) . In addition, PGE 2 production stimulated by EGF ϩ ionomycin was attenuated significantly in the COS-1 cells expressing the S511A/S515A double mutant compared with WT (Fig. 10A) , whereas the expression levels of WT and double mutant were comparable (Fig. 10B) . Basal PGE 2 levels in iPLA 2 ␥ WT and S511A/S515A-expressing cells appeared comparable (Fig.  10A ).
Next, we tested if Ser-511 in iPLA 2 ␥ WT was phosphorylated by EGF ϩ ionomycin stimulation using an antibody that identifies the (R/K)XX(pS/T) motif, corresponding to KLGpS in iPLA 2 ␥. Phosphorylation of Ser-511 was evident in stimulated cells; in some experiments, faint phosphorylation was detected in unstimulated cells (Fig. 10C) . In contrast, the S511A/S515A mutant iPLA 2 ␥ was not phosphorylated by EGF ϩ ionomycin (Fig 10C) , confirming that in the WT enzyme Ser-511 is the relevant phosphorylation site. These results suggest that the iPLA 2 ␥ activation by EGF ϩ ionomycin is mediated by the direct phosphorylation of iPLA 2 ␥ by a kinase, which is downstream of ERK. Phosphorylation of Ser-515 in iPLA 2 ␥ WT was not monitored due to the unavailability of an antibody that identifies the DVFpSQ motif.
In a previous study we demonstrated that complement induced a robust activation-specific phosphorylation of MK2 (ϳ4-fold above control) and that activation of MK2 was mediated by both ERK and p38 kinase pathways (51) . Indeed, MK2 is regarded primarily as a substrate of p38 kinase but is also reported to be a substrate of ERK (44, 51) . Given that Ser-511 and Ser-515 may represent a MK2 phosphorylation motif, we investigated if expression of MK2 would stimulate the activity of iPLA 2 ␥ WT. By analogy to constitutively active MEK1 and MEKK1 (as shown in Fig. 6 ), WT and constitutively active MK2 were expressed with iPLA 2 ␥ WT in COS-1 cells. Despite robust expression, neither WT nor constitutively active MK2 stimulated PGE 2 production consistently (data not shown).
Another protein kinase that is activated by ERK and p38 is MNK1 (44) . To determine if the effect of the ERK pathway on iPLA 2 ␥ activation was mediated by MNK1, we expressed GFPiPLA 2 ␥ in COS-1 cells and examined PGE 2 production after stimulation with EGF ϩ ionomycin in the presence or absence of the MNK1-directed inhibitor CGP57380 (44) . Stimulated PGE 2 production was blocked completely by CGP57380 (Table  2) . CGP57380 was reported to have some inhibitory activity against MEK1 (44); however, we verified that EGF-induced phosphorylation of ERK was not reduced in the presence of CGP57380 (result not shown). Therefore, inhibition of the EGF ϩ ionomycin-induced activation of iPLA 2 ␥ was most likely due to the inhibition of MNK1. To confirm that MNK1 can activate and phosphorylate iPLA 2 ␥, COS-1 cells were transfected with WT GFP-iPLA 2 ␥ and COX1 in the presence of WT, constitutively active (T332D), or dominant interfering (T2A2) forms of MNK1 or with empty vector. Both MNK1 WT and T332D enhanced PGE 2 production compared with control (vector), whereas MNK1 T2A2 did not show a significant effect (Fig. 11, A and B) . We tested Ser-511 phosphorylation by constitutively active MNK1 in iPLA 2 ␥ WT using the anti-(R/K)XX(pS/T) antibody. Phosphorylation of Ser-511 was enhanced when COS-1 cells were cotransfected with MNK1 T332D compared with empty vector (Fig. 11, C and D) . Together these results support the view that phosphorylation of iPLA 2 ␥ on Ser-511 in response to EGF stimulation is mediated by MNK1.
Complement Induces Phosphorylation of iPLA 2 ␥ on Ser-511-In these experiments we assessed if complement-mediated activation of iPLA 2 ␥ involves phosphorylation. First, we tested if Ser-511 in iPLA 2 ␥ WT is phosphorylated by complement in GECs using the anti-(R/K)XX(pS/T) antibody. Phosphorylation of Ser-511 was stimulated in complement-treated GECs (NS) FIGURE 9 . Mutations in putative ERK phosphorylation sites do not affect iPLA 2 ␥ activity. COS-1 cells were transiently transfected with M1-GFP-iPLA 2 ␥ WT, the S168A and S271A mutants, or the S168A/S271A double mutant together with COX1. A, after 24 h, cells were untreated or were incubated with EGF (100 ng/ml) ϩ ionomycin (Iono, 1.5 M) for 40 min. PGE 2 release was stimulated significantly by EGF ϩ ionomycin in the cells expressing M1 GFP-iPLA 2 ␥ WT and all mutants. *, p Ͻ 0.05; **, p Ͻ 0.01 versus corresponding untreated groups, seven experiments. In these experiments basal PGE 2 release (vector ϩ COX1-transfected, untreated cells) was 827 pg/ml. B, cell lysates were immunoblotted with antibodies to GFP or tubulin. The blot shows comparable levels of expression. compared with control (HIS; Fig. 12A ). In some experiments ionomycin was included together with NS and HIS incubations; however, ionomycin did not modulate Ser-511 phosphorylation either in complement-treated cells or control (Fig. 12A) . Because complement increases the cytosolic Ca 2ϩ concentration (16, 52) , ionomycin would not be expected to provide any additional stimulatory effect. Second, we compared complement-induced PGE 2 release in GECs expressing M1 GFPiPLA 2 ␥ WT or GFP-iPLA 2 ␥ S511A/S515A and GEC-Neo. Overexpression of M1 GFP-iPLA 2 ␥ WT or the S511A/S515A mutant did not affect the basal PGE 2 production (during incubation with HIS). After incubation with complement (NS), PGE 2 release was significantly amplified in cells expressing M1 GFP-iPLA 2 ␥ compared with GEC-Neo (Fig. 12B ), in keeping with previous experiments (Fig. 4, B and D) . PGE 2 release in complement-treated cells expressing the S511A/S515A mutant was significantly lower compared with WT (Fig. 12B ) despite comparable levels of expression (Fig. 12C) . Together, these results indicate that complement at least in part activates iPLA 2 ␥ via direct phosphorylation on Ser-511, most likely by MNK1.
DISCUSSION
The present study demonstrates that complement C5b-9 activates endogenous and ectopic iPLA 2 ␥ (Fig. 4) . Activation of iPLA 2 ␥ occurs via ERK and p38 pathways (Fig. 5-9 ) and is dependent on an increase in cytosolic Ca 2ϩ concentration and phosphorylation of the enzyme on Ser-511 and/or Ser-515 most likely via MNK1 (Fig. 11, Table 2 ). To our knowledge this is the first demonstration of phosphorylation-dependent activation of iPLA 2 ␥. Stimulation of iPLA 2 ␥ by complement was coupled with production of PGE 2 . Similar to this result in the present study, iPLA 2 ␥ was shown to augment AA release and PGE 2 production, which was associated with increased cell growth in a human colorectal adenocarcinoma cell line (HAC-7) (17). Coupling of iPLA 2 ␥ with COX1 was also shown in HEK293 cells (17) .
In the present study we examined the cellular localization of iPLA 2 ␥ to better understand the mechanisms by which iPLA 2 ␥ hydrolyzes membrane phospholipids. M1 GFP-iPLA 2 ␥ WT was found mainly in the perinuclear region and co-localized with markers of the ER and mitochondria (Fig. 2) . Deletion of the 220-amino acid N-terminal region (M4 GFP-iPLA 2 ␥) altered the localization of the enzyme such that a significant portion of M4 GFP-iPLA 2 ␥ shifted to the cytosol (Fig. 2) . Our result is in keeping with the study of Tanaka et al. (34) , which showed that deletion of a 362-amino acid N-terminal region of iPLA 2 ␥ caused a portion of the enzyme to shift from the membrane to the cytosol in a cell fractionation study. Moreover, the N-terminal fragment localized solely in the membrane but not in the cytosolic fraction (34) . Deletion of the N-terminal region of iPLA 2 ␥ did not abolish iPLA 2 ␥ enzymatic activity in vitro (Fig. 3D) , consistent with the study by Tanaka et al. (34) . However, the N-terminal truncated form of iPLA 2 ␥ was unable to induce significant PGE 2 production when expressed in cells (Fig. 3) . Taken together, these results indicate that the N-terminal region is involved in the membrane association of iPLA 2 ␥, thereby allowing the enzyme access to phospholipid substrate intracellularly. In addition, the N-terminal region may have positive regulatory elements that could enhance iPLA 2 ␥ activity. Mislocalization of M4 GFP-iPLA 2 ␥ from the membrane may be expected to reduce PGE 2 production, as COX1 is localized in the ER membrane and would couple with iPLA 2 ␥-mediated AA release (17) .
In previous studies it was demonstrated that C5b-9 can activate cPLA 2 (16, 52) . Thus, both cPLA 2 ␣ and iPLA 2 ␥ can contribute to complement-dependent release of AA. Previous studies in GECs demonstrated that complement induced an increase in cPLA 2 ␣ catalytic activity, in association with Ser-505 phosphorylation, although this phosphorylation was not essential for cPLA 2 ␣ activation (12, 13) . In addition, glomerular cPLA 2 ␣ was phosphorylated in vivo in passive Heymann nephritis (51) .
By analogy to cPLA 2 ␣, complement activated iPLA 2 ␥ through intermediate signals, including protein kinases. C5b-9 can activate MAPK pathways in GECs (12, 13) . In GECs overexpressing GFP-iPLA 2 ␥ WT, the complement-induced release of PGE 2 was blocked by two distinct chemical inhibitors of both the ERK and p38 pathways but not JNK (Fig. 5) . Conversely, constitutively active MAPK pathway mutants (in particular MEK and MEKK1) increased iPLA 2 ␥-dependent PGE 2 production (Fig. 6) . Both MEK and MEKK1 induced activation-specific phosphorylation of ERK (Fig. 7) . Taken together, the ERK and p38 pathways can mediate the activation of iPLA 2 ␥ by complement. A role for MAPKs in the activation of iPLA 2 has been reported previously. Thrombin stimulated both ERK and p38 and iPLA 2 activity in vascular smooth muscle cells and ventricular myocytes (53, 54) . In mouse neural cells, p38 facilitated iPLA 2 activity during hypoxia (55) . These studies did not, however, differentiate between iPLA 2 ␤ and iPLA 2 ␥. To further substantiate the role of the ERK pathway in the activation of iPLA 2 ␥, we showed that EGF ϩ ionomycin stimulated PGE 2 release in COS-1 cells expressing GFP-iPLA 2 ␥ WT in association with ERK activation (Figs. 8 and 9 ). Interestingly, unlike the constitutively active mutants of MEK1, MKK3, or MEKK1, the stimulatory effect of EGF in cells required the addition of ionomycin (to increase the cytosolic Ca 2ϩ concentration) despite the Ca 2ϩ -independent catalytic properties of iPLA 2 ␥ in vitro. In keeping with previous reports, this finding suggests that activation of iPLA 2 ␥ in agonist-stimulated cells may involve a Ca 2ϩ -regulated process (5, 6) , possibly activation of Ca 2ϩ -dependent protein kinases, such as calmodulin (56) . Alternatively, Ca 2ϩ may enhance activation of iPLA 2 ␥ directly. A recent study showed that divalent cations (Ca 2ϩ or Mg 2ϩ ) can activate iPLA 2 ␥ in heart mitochondria, leading to release of eicosanoids and lysolipids, possibly by facilitating mitochondrial phospholipid hydrolysis by iPLA 2 ␥ (57).
Tanaka et al. (6) suggested that iPLA 2 ␥ may have multiple potential phosphorylation sites. We carried out a mutagenesis analysis of iPLA 2 ␥ to determine the regulation of iPLA 2 ␥ activity by the ERK pathway. Mutation of two putative ERK phosphorylation sites, i.e. S168A and S271A, and S168A/S271A double mutation did not abrogate the stimulated activity of iPLA 2 ␥ WT (Fig. 9) , implying that iPLA 2 ␥ was not a direct target of ERK. Another report suggested that the MAPK pathway might be involved in iPLA 2 ␥ activation indirectly, but no supporting data were presented (17) . Based on a phosphoproteomic analysis of murine cardiac mitochondrial proteins (50), we then mutated Ser-511 and Ser-515 to Ala and showed that this double mutation significantly attenuated EGF ϩ ionomycin-as well as complement-stimulated iPLA 2 ␥-dependent PGE 2 production (Figs. 10 and 12) . Moreover, phosphorylation of Ser-511 was induced by EGF ϩ ionomycin and by complement (Figs. 10 and 12) . Phosphorylation of Ser-511 and/or Ser-515 could induce a conformational change in the enzyme, lead- Phosphorylation is absent in the HIS-stimulated cells. B, GEC neo and GECs that express M1 GFP-iPLA 2 ␥ WT or GFP-iPLA 2 ␥ S511A/S515A (transient transfection) were incubated with antibody and complement as above. PGE 2 production was amplified in NS-stimulated M1 GFP-iPLA 2 ␥ WT-expressing cells, whereas the amplification was smaller in GECs expressing the double mutant. *, p Ͻ 0.001 M1 GFP-iPLA 2 ␥ WT (NS) versus GEC-Neo (NS) and **, p Ͻ 0.05 M1 GFP-iPLA 2 ␥ WT (NS) versus GFP-iPLA 2 ␥ S511A/S515A (NS), three experiments. C, cell lysates were immunoblotted with antibodies to GFP or actin. The blot shows comparable levels of GFP-iPLA 2 ␥ expression.
